KRYS

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Krystal Biotech received UK MHRA approval for VYJUVEK to treat dystrophic epidermolysis bullosaMay 18, 2026
• Krystal Biotech received FDA RMAT designation for KB707 in advanced or metastatic non-small cell lung cancerFeb 9, 2026
• Krystal Biotech to announce interim update from Phase 1 CORAL-1 study of KB407Jan 8, 2026
• Krystal Biotech receives FDA platform technology designation for HSV-1 viral vector used in KB801 for treatment of neurotrophic keratitisOct 14, 2025
• Krystal Biotech announces FDA approval of updated VYJUVEK® labelSep 15, 2025